CombiChem receives extension for drug- discovery collaboration agreement with Teijin Ltd. of Japan.SAN DIEGO--(BW HealthWire)--May 5, 1997--CombiChem Inc. has signed a one-year extension of its drug-discovery collaboration agreement with Teijin Ltd. of Japan. CombiChem accelerates discovery through the integration of proprietary molecular-design technology and rapid synthesis with chemistry expertise. The rapidly growing company has attracted top venture-capital investors and project partners, such as Roche Bioscience, from the pharmaceutical industry. The agreement enables CombiChem and Teijin to continue work on projects started last year to discover antagonists antagonists, n muscles that counterbalance agonists during specific movements. opioid Neurology A pain-attenuating peptide that occurs naturally in the brain, which induces analgesia by mimicking endogenous opioids at opioid of specific G-protein coupled receptor targets. CombiChem is designing and synthesizing compound libraries based on work initiated at Teijin. Teijin is providing screening, chemistry and biological support. Vicente Anido Jr., Ph.D., chief executive officer and president of CombiChem said: ''The extension of the agreement with Teijin is significant because it is a continuing affirmation A solemn and formal declaration of the truth of a statement, such as an Affidavit or the actual or prospective testimony of a witness or a party that takes the place of an oath. An affirmation is also used when a person cannot take an oath because of religious convictions. of CombiChem's unique Discovery Engine and its integration of proprietary molecular design, rapid synthesis and chemistry. This is just another step in what we expect will be a long-term relationship between our company and Teijin.'' ''We expect that CombiChem's Discovery Engine will continue to add a powerful new technology to our drug discovery process and enable us to identify lead compounds within significantly shorter periods of time,'' said Seizi Kurozumi, Ph.D., Teijin's general manager, planning department, Medical & Pharmaceutical Group. The original agreement consists of an upfront payment by Teijin, as well as research support, significant milestone payments and royalties which could lead to revenues for CombiChem in excess of $10 million over the life of the contract. Additionally, CombiChem has retained the North and South American rights to develop and market any product resulting from the collaboration. CombiChem, founded in 1994, accelerates discovery through the integration of proprietary molecular-design technology and rapid synthesis with chemistry expertise. Customers benefit from the acceleration of compound time to market, amplification amplification /am·pli·fi·ca·tion/ (33000) (am?pli-fi-ka´shun) the process of making larger, such as the increase of an auditory stimulus, as a means of improving its perception. of current R&D resources, enhancement of patent strength and maximizing the probability of development success. In addition to its current agreements, CombiChem is negotiating several new strategic research collaborations with pharmaceutical, biotechnology and agrochemical agrochemical Any chemical used in agriculture, including chemical fertilizers, herbicides, and insecticides. Most are mixtures of two or more chemicals; active ingredients provide the desired effects, and inert ingredients stabilize or preserve the active ingredients or aid companies in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , Europe and Japan. Teijin Ltd. is a corporation with headquarters in Tokyo, where it is engaged in pharmaceutical and home health-care businesses, as well as synthetic fibers Noun 1. synthetic fiber - fiber created from natural materials or by chemical processes man-made fiber fiber, fibre - a slender and greatly elongated substance capable of being spun into yarn acrylic, acrylic fiber - polymerized from acrylonitrile and plastics. CombiChem is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. with headquarters in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. . The address is 9050 Camino Santa Fe Santa Fe, city, Argentina Santa Fe, city (1991 pop. 341,000), capital of Santa Fe prov., NE Argentina, a river port near the Paraná, with which it is connected by canal. , San Diego, Calif. 92121. CONTACT: CombiChem Inc., San Diego Vicente Anido Jr., Ph.D., 619/530-0484 or Friestedt International, San Diego Susanne Friestedt, 619/223-8844 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion